INCYIncyte Corporation
# 1 · $115.71 (-1.04%) · $23.45B · Healthcare
52-week range
Market data
- P/E
- 14.74
- 1M
- -7.02%
- 1Y
- +29.56%
- Yield
- —
- RSI
- 53.39
- MACD
- +0.54%
Breakdown
Why
- P/E of 14.7
- free cash flow yield 8.1%
- earnings growth of +46.7% a year over 2 years (+3845.0% in the latest year alone, inflated by an unusually low prior year)
- revenue growth of 21.2%
- ROE of 25.4%
- profit margin of 27.7%
- margin and ROA expanding YoY
- 12-1 momentum return of 39.3%
- trading 7.4% above 200d SMA
- MACD histogram positive
- EPS vs. estimates: +27.8% on average
Rationale is generated by the scoring engine (English).
Piotroski F-Score
7
7 / 9 checks passed
- roa positive
- ocf positive
- roa improving
- accruals
- leverage decreasing
- liquidity improving
- no dilution
- margin improving
- turnover improving
Altman Z-Score
Risk signals
- Share dilutionInfo
shares outstanding higher than the previous fiscal year
- Geographic revenue concentrationInfo
93% of revenue from United States
- Product revenue concentrationInfo
85% of revenue from Products
Company research
Business Overview Incyte Corporation is a global biopharmaceutical company that discovers, develops, and commercializes small-molecule and biologic medicines, generating revenue primarily from net product sales of marketed therapies including Jakafi (ruxolitinib), Opzelura (ruxolitinib) cream, Iclusig (ponatinib), Pemazyre (pemigatinib), Monjuvi/Minjuvi (tafasitamab), and Zynyz (retifanlimab). Market Position Incyte’s commercial portfolio is anchored by Jakafi in hematology/oncology and the faster-growing dermatology franchise Opzelura, with differentiation rooted in internally developed JAK-pathway expertise and an R&D pipeline spanning oncology and inflammation/autoimmunity. Key Segments The company reports one operating and reportable segment (integrated biopharmaceutical operations), with revenues disaggregated primarily by product and by royalties/other collaboration revenues.
AI-generated summary based on third-party data; it may contain errors. Not investment advice or a recommendation to invest.
Period: 2021-12-31 → 2025-12-31